Effect of Soy Isoflavones Supplementation on Adiponectin Levels in Postmenopausal Women


Soy isoflavones
Soy food
Postmenopausal women

How to Cite

Tutunchi, S. ., Koushki, M., Amiri-Dashatan, N. ., Khodabandehloo, H., Hosseini, H., Panahi, G., Hashemi, J., Karbalaee-Hasani, A. ., Majidi, Z., & Rezaei-Tavirani, M. (2021). Effect of Soy Isoflavones Supplementation on Adiponectin Levels in Postmenopausal Women: A Meta-Analysis . Journal of Pharmacy and Nutrition Sciences, 11, 184–195. https://doi.org/10.29169/1927-5951.2021.11.21


Decreased adiponectin levels has been demonstrated in postmenopausal (PMP) women. Soy isoflavones, as an herbal product have been shown to increase adiponectin level but the results are inconclusive and inconsistent. The present study reassessed the data on the impact of soy isoflavones supplementation on adiponectin levels in PMP women through a meta-analysis. A systematic search was performed in the databases of PubMed, Web of science, Scopus and the Cochrane library. The literature search identified 830 studies with duplicates. Out of those, 80 were screened for title and abstract and 12 articles were ultimately selected for the analysis. Meta-regression and subgroup analyses, based on the moderator variables such as treatment duration, dose of soy isoflavones and BMI were performed. The quality of the studies was evaluated using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. The results revealed that soy isoflavones supplementation significantly increased the circulating level of adiponectin in PMP women (SMD: 0.36 µg/mL; 95% CI (0.05 to 0.66); P= 0.02). No publication bias was observed using Begg's (P = 0.38) and Egger's (P = 0.07) tests. Sensitivity analysis indicated the results were completely powerful and stable. Moreover, Meta-regression and subgroup analyses indicated a significant increase of adiponectin levels in subgroups of dose > 50 mg and treatment duration less or equal 3 months. Our findings showed significantly increase in adiponectin levels after isoflavones-supplemented soy consumption in postmenopausal women, who received dose > 50 mg of soy isoflavones in treatment duration ≤ 3 months.



Faddy M, Gosden R. Ovary and ovulation: a model conforming the decline in follicle numbers to the age of menopause in women. Human Reproduction 1996;. 11(7): 1484-1486. https://doi.org/10.1093/oxfordjournals.humrep.a019422

McKinlay SM. The normal menopause transition: an overview. Maturitas 1996; 23(2): 137-45. https://doi.org/10.1016/0378-5122(95)00985-X

Di Carlo C, et al. Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy. Menopause 2004; 11(4): 466-73. https://doi.org/10.1097/01.GME.0000109313.11228.2B

Jassi H, et al. Effect of soy proteins vs soy isoflavones on lipid profile in postmenopausal women. Indian Journal of Clinical Biochemistry 2010; 25(2): 201-207. https://doi.org/10.1007/s12291-010-0036-8

Christie DR, et al. Metabolic effects of soy supplementation in postmenopausal Caucasian and African American women: a randomized, placebo-controlled trial. American Journal of Obstetrics and Gynecology 2010; 203(2): 153. e1-153. e9. https://doi.org/10.1016/j.ajog.2010.02.058

Silha JV, et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. European Journal of Endocrinology 2003; 149(4): 331-336. https://doi.org/10.1530/eje.0.1490331

Hroussalas G, et al. Leptin, soluble leptin receptor, adiponectin and resistin in relation to OGTT in overweight/obese postmenopausal women. Maturitas 2008; 59(4): 339-349. https://doi.org/10.1016/j.maturitas.2008.03.012

Silha JV, et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. European Journal of Endocrinology 2003; 149(4): 331-335. https://doi.org/10.1530/eje.0.1490331

Koushki M, et al. Resveratrol: A miraculous natural compound for diseases treatment. Food Science & Nutrition 2018; 6(8): 2473-2490. https://doi.org/10.1002/fsn3.855

Koushki M, Dashatan NA, Meshkani R. Effect of resveratrol supplementation on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. Clinical Therapeutics 2018; 40(7): 1180-1192. e5. https://doi.org/10.1016/j.clinthera.2018.05.015

Koushki M, et al. Effect of garlic intake on inflammatory mediators: a systematic review and meta-analysis of randomised controlled trials. Postgraduate Medical Journal 2020. https://doi.org/10.1136/postgradmedj-2019-137267

Koushki M, et al. Therapeutic effects of hydro-alcoholic extract of Achillea wilhelmsii C. Koch on indomethacin-induced gastric ulcer in rats: a proteomic and metabolomic approach. BMC Complementary and Alternative Medicine 2019; 19(1): 205. https://doi.org/10.1186/s12906-019-2623-4

Kwon DY, et al. Antidiabetic effects of fermented soybean products on type 2 diabetes. Nutrition Research 2010; 30(1): 1-13. https://doi.org/10.1016/j.nutres.2009.11.004

González S, et al. Effects of isoflavone dietary supplementation on cardiovascular risk factors in type 2 diabetes. Diabetes Care 2007; 30(7): 1871-1873. https://doi.org/10.2337/dc06-1814

Brandi M. Natural and synthetic isoflavones in the prevention and treatment of chronic diseases. Calcified Tissue International 1997; 61(1): S5-S8. https://doi.org/10.1007/s002239900376

Riesco E, et al. Effect of exercise training combined with phytoestrogens on adipokines and C-reactive protein in postmenopausal women: a randomized trial. Metabolism 2012; 61(2): 273-280. https://doi.org/10.1016/j.metabol.2011.06.025

Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009; 6(7): e1000097. https://doi.org/10.1371/journal.pmed.1000097

Jadad AR, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials 1996; 17(1): 1-12. https://doi.org/10.1016/0197-2456(95)00134-4

Guyatt GH, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336(7650): 924-926. https://doi.org/10.1136/bmj.39489.470347.AD

Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13. https://doi.org/10.1186/1471-2288-5-13

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; p. 1088-1101. https://doi.org/10.2307/2533446

Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-634. https://doi.org/10.1136/bmj.315.7109.629

Borenstein M, et al. Comprehensive meta-analysis version 2. Englewood, NJ: Biostat 2005; 104.

Mankowska A, Nowak L, Sypniewska G. Adiponectin and Metabolic Syndrome in Women at Menopause. Ejifcc 2009; 19(4): 173-84.

Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin--the classical, resistin--the controversical, adiponectin--the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19(4): 525-46. https://doi.org/10.1016/j.beem.2005.07.008

Karbowska J, Warczak E, Kochan Z. [Adiponectin gene polymorphism and protein dysfunction in the development of insulin resistance]. Postepy Hig Med Dosw (Online) 2004; 58: 449-57.

Ryo M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68(11): 975-81. https://doi.org/10.1253/circj.68.975

Stork S, et al. Low levels of adiponectin predict worsening of arterial morphology and function. Atherosclerosis 2007; 194(2): e147-53. https://doi.org/10.1016/j.atherosclerosis.2006.11.044

Miyatani Y, et al. Associations of circulating adiponectin with estradiol and monocyte chemotactic protein-1 in postmenopausal women. Menopause 2008; 15(3): 536-41. https://doi.org/10.1097/gme.0b013e31815c85ed

Engeli S, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003; 52(4): 942-7. https://doi.org/10.2337/diabetes.52.4.942

Lobo RA, Metabolic syndrome after menopause and the role of hormones. Maturitas 2008; 60(1): 10-8. https://doi.org/10.1016/j.maturitas.2008.02.008

Lu JY, et al. Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci 2008; 15(5): 565-76. https://doi.org/10.1007/s11373-008-9261-z

D’Anna R, et al. Effects of a new flavonoid and Myo-inositol supplement on some biomarkers of cardiovascular risk in postmenopausal women: a randomized trial. International Journal of Endocrinology 2014; 2014. https://doi.org/10.1155/2014/653561

Lozovoy MAB, et al. Blood pressure decrease with ingestion of a soya product (kinako) or fish oil in women with the metabolic syndrome: role of adiponectin and nitric oxide. British Journal of Nutrition 2012; 108(8): 1435-1442. https://doi.org/10.1017/S0007114511006921

Llaneza P, et al. Soy isoflavones, diet and physical exercise modify serum cytokines in healthy obese postmenopausal women. Phytomedicine 2011; 18(4): 245-50. https://doi.org/10.1016/j.phymed.2010.07.011

Matvienko OA, et al. Appetitive hormones, but not isoflavone tablets, influence overall and central adiposity in healthy postmenopausal women. Menopause 2010; 17(3): 594-601. https://doi.org/10.1097/gme.0b013e3181c92134

Maskarinec G, et al. Inflammatory markers in a 2-year soy intervention among premenopausal women. J Inflamm (Lond) 2009; 6: 9. https://doi.org/10.1186/1476-9255-6-9

Wildman R, et al. Adipocytokine and ghrelin levels in relation to cardiovascular disease risk factors in women at midlife: longitudinal associations. International Journal of Obesity 2008; 32(5): 740-748. https://doi.org/10.1038/sj.ijo.0803782

Sites CK, et al. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertility and Sterility 2002; 77(1): 128-135. https://doi.org/10.1016/S0015-0282(01)02934-X

Llaneza P, et al. Soy isoflavones, diet and physical exercise modify serum cytokines in healthy obese postmenopausal women. Phytomedicine 2011; 18(4): 245-250. https://doi.org/10.1016/j.phymed.2010.07.011

Maskarinec G, et al. Inflammatory markers in a 2-year soy intervention among premenopausal women. Journal of Inflammation 2009; 6(1): 1-7. https://doi.org/10.1186/1476-9255-6-9

Jayagopal V, et al. Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care 2002; 25(10): 1709-1714. https://doi.org/10.2337/diacare.25.10.1709

Arner P. Insulin resistance in type 2 diabetes-role of the adipokines. Current Molecular Medicine 2005; 5(3): 333-339. https://doi.org/10.2174/1566524053766022

Huang Y, et al. Decreased circulating levels of tumor necrosis factor-α in postmenopausal women during consumption of soy-containing isoflavones. The Journal of Clinical Endocrinology & Metabolism 2005; 90(7): 3956-3962. https://doi.org/10.1210/jc.2005-0161

Penza M, et al. Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. Endocrinology 2006; 147(12): 5740-5751. https://doi.org/10.1210/en.2006-0365

Gong L, et al. Inactivation of NF-κ B by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 2003; 22(30): 4702-4709. https://doi.org/10.1038/sj.onc.1206583

Chiang H-S, et al. UVB-protective effects of isoflavone extracts from soybean cake in human keratinocytes. International Journal of Molecular Sciences 2007; 8(7): 651-661. https://doi.org/10.3390/i8070651

Valsecchi AE, et al. The soy isoflavone genistein reverses oxidative and inflammatory state, neuropathic pain, neurotrophic and vasculature deficits in diabetes mouse model. European Journal of Pharmacology 2011; 650(2-3): 694-702. https://doi.org/10.1016/j.ejphar.2010.10.060

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright (c) 2021 Sara Tutunchi, Mehdi Koushki, Nasrin Amiri-Dashatan, Hadi Khodabandehloo, Hossein Hosseini, Godratollah Panahi, Javad Hashemi, Amir Karbalaee-Hasani, Ziba Majidi, Mostafa Rezaei-Tavirani